Teijo
Saari
Professor, Anaesthesiology, Intensive Care
MD, PhD. Head of Department
Precise and new therapeutic possibilities to acute pain medicine.
Contact
Areas of expertise
Pain medicine
Analgesia
Modelling & Simulation
Pharmacometrics
Clinical Pharmacology
Drug-Drug-Interactions
Biography
Professor Teijo Saari (MD, PhD, University of Turku) is a specialist in anesthesiology and intensive care and cardiac anesthesia at the Turku University Hospital, Turku, Finland. Since 2004, he has been conducting research on clinical pharmacology examining the pain therapeutics and anesthetics and developing pharmacometric models for precise drug dosing. His PhD work evaluated drug-drug interactions between antimycotes and drugs used in anesthesiology and pain medicine (University of Turku, April 2005). In 2011-2013 he worked as post doctoral
fellow in University of Erlangen-Nuremberg, Germany in pharmacometric
research project: ’PEP’ – Personalized Effect-Controlled
Pharmacotherapy. Since 2013, he has lead his research group focusing on acute pain medicine. In January 2017, he was appointed to Tenure Track as Associate Professor and in June 2021 as Full Professor and Chairman of Anesthesiology and Intensive Care at the University of Turku.
His career publications total is 57 (h-index 20) with published highlights including high-ranked papers in Anesthesiology, British Journal of Anesthesiology and Clinical Pharmacokinetics.
His career publications total is 57 (h-index 20) with published highlights including high-ranked papers in Anesthesiology, British Journal of Anesthesiology and Clinical Pharmacokinetics.
Teaching
Teaching responsibilities: 1) Anesthesiology and Intensive care for medical students, 2) Graduate studies for MDs
Special interest areas: Acute pain medicine, cardiac anesthesia, clinical pharmacology
Special interest areas: Acute pain medicine, cardiac anesthesia, clinical pharmacology
Research
Professor Saari's principal research focus has been to provide novel information on therapeutics used in acute pain medicine. Beginning from 2013 he has led a research group with special interest on model-informed precision dosing and development of new dosing modalities for pain therapeutics. Important aspect of his research has been a pursuit to reduce opioid use with adjuvants added to the opioid therapy in the postoperative setting. His work has demonstrated that pharmacometric models can improve the precision of drug dosing during postoperative phase. Furthermore, his studies have established covariate effects explaining between-patient variability. His future aim is to discover biomarkers that can predict chronic pain development.
Publications
Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone A Randomized, Three-Phase, Crossover, Placebo-Controlled Study (2011)
Clinical Drug Investigation
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Enhancement of GABAergic activity:neuropharmacological effects of benzodiazepines and therapeutic use in anaesthesiology (2011)
Pharmacological Reviews
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects (2011)
European Journal of Clinical Pharmacology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Grapefruit Juice Enhances the Exposure to Oral Oxycodone (2010)
Basic and Clinical Pharmacology and Toxicology Supplement
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Väliaikainen ulkoinen tahdistus (2010)
Spirium
(Artikkeli ammattilehdessä tai kirjoitus ammatillisessa blogissa (D1))
Effect of Telithromycin on the Pharmacokinetics and Pharmacodynamics of Oral Oxycodone (2010)
Journal of Clinical Pharmacology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone (2010)
British Journal of Clinical Pharmacology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine (2010)
European Journal of Pain
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
St John's wort greatly reduces the concentrations of oral oxycodone (2010)
European Journal of Pain
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir (2010)
European Journal of Clinical Pharmacology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))